Neptunus Bioengineering Holdings To Transfer Beidouxing Pharmaceutical
This article was originally published in PharmAsia News
Neptunus Bioengineering Holdings plans to transfer its 100 percent stake in Changchun Beidouxing Pharmaceutical for RMB 40 million to Texas Petroleum. In addition, the company and its subsidiary Neptunus Interlong Bio-technique will sign a letter of intent on equity transfer and assets acquisition. To beef up Interlong's profit-making capability, Neptunus Bioengineering and its holding subsidiary Neptunus Medicine intend to sell their respective 75 percent and 5 percent stakes in Fuzhou Neptunus Futao Pharmaceuticals to Interlong. Interlong will on its part transfer its interferon and interleukin business to Neptunus Medicine. (Click here for more - Chinese Language)
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.